Northeastern Pa. HIE signs Covisint for clinical messaging

Jeff Byers | | Health Exec | Informatics
Northeastern Pennsylvania Health Information Exchange (NEPA HIE) has selected cloud computing software developer Covisint to assist with clinical messaging support.

With Covisint ExchangeLink, NEPA HIE physicians will receive the clinical and administrative information at the point of care, according to Covisint.

NEPA HIE enlisted Covisint to expedite adoption of healthcare technology among member physicians. NEPA HIE also will use Covisint's platform-as-a-service, Covisint ExchangeLink for Healthcare, to minimize workflow disruption, the Detroit-based company stated.

Jeff Byers

Related Content

Alabama security breach exposes personal information of cardiologists, heart patients
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Best in KLAS 2024: New rankings for cardiovascular information systems, hemodynamic solutions
Best in KLAS 2024 rankings released, showcasing medical imaging IT systems
Cloud image storage for radiology is a growing trend in healthcare
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.